Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features
Funding The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest Matt Shirley is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.
information about this Adis Drug Review can be found here.
Starting with the first-in-class agent ibrutinib, the development of
Bruton tyrosine kinase (BTK) inhibitors has led to dramatic improvements in the
management of B-cell malignancies. Subsequently, more-highly selective
second-generation BTK inhibitors (including acalabrutinib, zanubrutinib, tirabrutinib
and orelabrutinib) have been developed, primarily with an aim to reduce
off-target toxicities. More recently, third-generation agents including the
non-covalent BTK inhibitors pirtobrutinib and nemtabrutinib have entered
later-stage clinical development. BTK inhibitors have shown strong activity in
a range of B-cell malignancies, including chronic lymphocytic leukaemia/small
lymphocytic lymphoma, mantle cell lymphoma, Waldenström’s macroglobulinaemia
and marginal zone lymphoma. The agents have acceptable tolerability, with
adverse events generally being manageable with dosage modification. This review
article summarises the evidence supporting the role of BTK inhibitors in the
management of B-cell malignancies, including
highlighting some differential features between agents.
© Springer Nature Switzerland AG 2021